Neuromuscular doc/researcher @TempleNeurology @ALSHF. Director, ALS Postmortem Core collab w CDC ALS Registry. Chair, DoD ALS Res. Prog Panel. Views my own.
Sculpture of the day. A neuromuscular junction with walnut neuron and cherry wood muscle. Maybe the tenth time I made this kind of piece, but the first time I made it so big. It is about 3ft tall.
Use code 447 and donate to the California ALS Research Network Voluntary Tax Contribution Fund this tax season. Help those living with ALS today.
Share this opportunity far and wide! Let’s make sure this program continues by making a contribution of any amount when you file your taxes.
For more information visit: https://t.co/0Guky3XiQ6
30 ALS orgs urge Congress to increase funding to fight ALS for people living today w. the incurable, fatal disease & those who will be diagnosed in the future, including military veterans who are at higher risk https://t.co/tJHrqKo5VK Click here to help: https://t.co/Cd4BvbSKIu
@youralsnetwork, in partnership with ALS United, will accept Letters of Intent for ALS research funding from March 16 – April 20, 2026.
As part of our ALS Research Innovation Initiative, we invite bold, imaginative proposals that push the field forward and accelerate progress toward better treatments and cures.
Apply for funding at https://t.co/xj44cvEJvl starting March 16. For questions about the process or the ALS Research Innovation Initiative, email [email protected].
@youralsnetwork, in partnership with ALS United, will accept Letters of Intent for ALS research funding from March 16 – April 20, 2026.
As part of our ALS Research Innovation Initiative, we invite bold, imaginative proposals that push the field forward and accelerate progress toward better treatments and cures.
Apply for funding at https://t.co/AU5oguCcnd starting March 16. For questions about the process or the ALS Research Innovation Initiative, email [email protected].
QurAlis is pleased to announce interim data from its ANQUR clinical trial which demonstrated QRL-201 had an effect on disease progression in #ALS patients; this effect was confirmed by markers of clinical efficacy and changes in a clinically relevant biomarker, along with target engagement.
These data support an open-label extended dosing period to the ANQUR clinical trial protocol under which all eligible trial participants will be given the opportunity to receive QRL-201 at the low dose of the dose-range finding portion of the study. The open-label extended dosing period to the ANQUR clinical trial has been approved in Canada and is currently under regulatory review in the European Union and the United Kingdom. In parallel, QurAlis is preparing to advance QRL-201 into a pivotal Phase 3 clinical trial in 2027.
QRL-201 is a first-in-class, potent antisense oligonucleotide (#ASO) #precisionmedicine in development to restore STATHMIN-2 (STMN2) expression in ALS patients with the aim to modify disease progression and improve outcomes. ANQUR (QRL-201-01; NCT05633459) is the first-ever clinical trial to evaluate a potential therapy to rescue STMN2 expression in people living with ALS. #neurodegenerativediseases #neurologicaldiseases https://t.co/0f6MfUd7Mu
Use code 447 this tax season and help those who are battling neurodegenerative diseases like ALS. Contribute to the California ALS Research Network Voluntary Tax Contribution Fund.
At least $250,000 must be raised annually for the program to remain on the CA income tax return form. Make an impact on ALS research today by contributing $1 or more. There is no maximum contribution amount!
Please share this opportunity far and wide! Learn more at: https://t.co/0Guky3XiQ6.
Please join us on February 12th at 4PM ET for Dr. Ernest Fraenkel's Distinguished Lecture - "What's a useful definition of a disease? Approaches for target discovery and patient stratification."
https://t.co/tv4W5YpaGH
@TempleResearch@TempleUniv@TempleHealth
Starts in 30 mins! Not only is Dr. Pattee a phenomenal neuromuscular clinician and scientist, he was my dad's medical student at UT Houston in the early 1980s! #BetterTogether#EndALS
🚨 Tonight! Our first Expert Talk of 2026 🚨
What if viruses play a role in ALS? Join us this evening as Dr. Gary Pattee explores emerging research in 🧬 “Chloroviruses in ALS” - a fascinating look at a lesser-known area of investigation that’s sparking important scientific questions.
📆 January 7
⏲️ 4 PM PT / 7 PM ET
🔗 https://t.co/kR91pnC56J
Curious minds welcome. Come learn with us. #ALS
@PatrickMoranTB Not that it matters, but extrapolating Thomas' total over a 17-game season would be 1,580 yards. Cook needs 166 yards over final 3 games to beat that. He still should do it as long as he plays all 3 games.
The #LongitudePrizeOnALS is a project around AI-based approaches to transform drug discovery for the treatment of ALS/MND. Delivered by Challenge Works & funded by the MND Association with FightMND + other funders. Applications close 3 Dec '25 15:00 GMT:https://t.co/ibmYG8Wkw6
Discussing how a local, regional and global network of ALS/MND champions will help to foster a #collaborative approach - a network of collective minds will help solve a big problem.
📢 Big news for @TempleNeurology Residency-- this year we are expanding our program and will recruit 1 advanced position in addition to our 6 categorical spots! Keep an eye out for our open house announcement soon - looking forward to meeting everyone! #neurotwitter#match2026
People living with ALS: ALS research counts on you!
When you join the Registry, you can complete risk factor surveys that will help researchers better understand ALS.
Join today: https://t.co/RhM2WaT68v